A number of Patients will have completed the Trial so still...

A number of Patients will have completed the Trial so still interim data but it will indicate any Serious Adverse Events..
As you know it can be really about avoiding the downside as much as identifying the upside..

To begin 2025, we’ll continue to collect and analyse the data from the on-going MF study.
We anticipate requesting feedback from the FDA on the next stage of clinical
development in Q2 2025, when we will have a number of patients with 12 months of
treatment data....

Just had a call with a few other Investors ,, not overly happy with the extremely light update in light of a 25% decline in SH Value over the past 2 weeks..NZT